ENG/中
美国
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
來凱醫藥-B
11.460
+0.160
1.42%
手動刷新
成交量:
124.70萬
成交額:
1,443.54萬
市值:
46.76億
市盈率:
-15.16
高:
11.960
開:
11.540
低:
11.220
收:
11.300
資料載入中...
總覽
公司
新聞
公告
來凱醫藥-B現漲超6% LAE102肥胖症I期多劑量遞增研究完成首例受試者訪視
新浪港股
·
03-26
港股異動 | 來凱醫藥-B(02105)漲超5% LAE102肥胖症I期多劑量遞增研究完成首例受試者訪視
智通财经
·
03-26
異動解讀 | 來凱醫藥-B盤中大漲5.24%,肥胖症新藥LAE102進入I期臨牀試驗
异动解读
·
03-26
來凱醫藥-B(02105.HK):LAE102針對肥胖症治療的I期多劑量遞增研究完成首例受試者訪視
格隆汇
·
03-26
來凱醫藥(2105.HK)發佈2024年度業績:核心臨牀研究快於預期 加強全球化合作
格隆汇
·
03-25
來凱醫藥-B(02105)發佈年度業績,研發費用2.15億元 計劃在3月啓動在中國的I期MAD研究
智通财经
·
03-24
來凱醫藥-B03月21日遭主力拋售53萬元
市场透视
·
03-21
來凱醫藥-B03月19日主力淨流入258萬元 散戶資金拋售
市场透视
·
03-19
來凱醫藥-B盤中異動 快速拉昇5.19%報13.380港元
市场透视
·
03-12
來凱醫藥-B盤中異動 早盤股價大跌5.04%
市场透视
·
03-11
港股通證券名單調整 被剔出個股股價普跌
金吾财讯
·
03-10
深交所發佈關於深港通下的港股通標的證券名單調整的公告
深交所网站
·
03-10
來凱醫藥-B03月06日獲主力加倉2196萬元
市场透视
·
03-06
港股創新藥ETF漲超2.5%,來凱醫藥-B漲超11%,機構:具有高科技屬性的醫藥醫療公司將更受市場青睞
21世纪经济报道
·
03-06
來凱醫藥-B(02105)股價顯著上升14.178%,現價港幣$15.14
阿斯达克财经
·
03-06
來凱醫藥-B盤中異動 大幅上漲5.13%
市场透视
·
03-06
來凱醫藥-B03月04日主力淨流入185萬元 散戶資金拋售
市场透视
·
03-04
港股異動 | 來凱醫藥-B(02105)再漲近5% 公司自研新藥LAE120獲美國FDA臨牀試驗批准
智通财经网
·
03-04
來凱醫藥-B盤中異動 股價大跌5.16%
市场透视
·
03-04
來凱醫藥-B03月03日遭主力拋售256萬元
市场透视
·
03-03
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02105/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02105","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02105\",,,,,undefined,":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"來凱醫藥-B","latestPrice":11.46,"timestamp":1744877289031,"preClose":11.3,"halted":0,"volume":1247000,"delay":0,"floatShares":408000000,"shares":408000000,"eps":-0.7560241273067456,"marketStatus":"休市中","change":0.16,"latestTime":"04-17 16:08:09","open":11.54,"high":11.96,"low":11.22,"amount":14435375,"amplitude":0.065487,"askPrice":11.52,"askSize":500,"bidPrice":11.46,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.7560241273067456,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":11.3,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":0.5022757481996416,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02105\",,,,,undefined,":{"symbol":"02105","floatShares":408000000,"roa":"-19.08%","roe":"-31.61%","lyrEps":-0.756024,"volumeRatio":0.5022757481996416,"shares":408000000,"dividePrice":0,"high":11.96,"amplitude":0.065487,"preClose":11.3,"low":11.22,"week52Low":3.9,"pbRate":"5.46","psRate":"8392.43","week52High":17.78,"institutionHeld":0,"latestPrice":11.46,"committee":0.333333,"eps":-0.7560241273067456,"divideRate":0,"volume":1247000,"delay":0,"ttmEps":-0.7560241273067456,"open":11.54,"prevYearClose":9.37,"prevWeekClose":10.64,"prevMonthClose":14.48,"prevQuarterClose":14.48,"fiveDayClose":9.32,"twentyDayClose":13.8,"sixtyDayClose":9.95},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02105\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522867938","title":"來凱醫藥-B現漲超6% LAE102肥胖症I期多劑量遞增研究完成首例受試者訪視","url":"https://stock-news.laohu8.com/highlight/detail?id=2522867938","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522867938?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 11:47","pubTimestamp":1742960820,"startTime":"0","endTime":"0","summary":" 来凯医药-B早盘上涨6.01%,现报13.76港元,成交额1666.66万港元。 来凯医药今日宣布,其自主研发的LAE102针对超重/肥胖在中国开展的I期临床试验进入了新阶段:继成功完成单剂量递增部分之后,多剂量递增研究已启动受试者招募,首例受试者昨天完成了首次访视。 MAD研究是一项随机、双盲、安慰剂对照研究,旨在评估皮下给药的LAE102在60名超重╱肥胖受试者中的安全性、耐受性、药代动力学和药效动力学。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-26/doc-ineqxyiq6174114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2522697548","title":"港股異動 | 來凱醫藥-B(02105)漲超5% LAE102肥胖症I期多劑量遞增研究完成首例受試者訪視","url":"https://stock-news.laohu8.com/highlight/detail?id=2522697548","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522697548?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 11:06","pubTimestamp":1742958390,"startTime":"0","endTime":"0","summary":"消息面上,来凯医药今日宣布,其自主研发的LAE102针对超重/肥胖在中国开展的I期临床试验进入了新阶段:继成功完成单剂量递增部分之后,多剂量递增研究已启动受试者招募,首例受试者昨天完成了首次访视。MAD研究是一项随机、双盲、安慰剂对照研究,旨在评估皮下给药的LAE102在60名超重╱肥胖受试者中的安全性、耐受性、药代动力学和药效动力学。此外,LAE102在美国的I期临床试验有望于二季度开始。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1137210087","title":"異動解讀 | 來凱醫藥-B盤中大漲5.24%,肥胖症新藥LAE102進入I期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1137210087","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137210087?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 11:00","pubTimestamp":1742958026,"startTime":"0","endTime":"0","summary":"来凯医药-B今日盘中大涨5.24%,股价表现强劲。这一涨幅与公司最新发布的积极研发进展密切相关。LAE102是来凯医药自主研发的针对ActRIIA的单克隆抗体,在临床前模型中显示出增加肌肉并减少脂肪的效果。值得注意的是,LAE102与GLP-1受体激动剂联用可进一步减少脂肪并显著降低GLP-1受体激动剂导致的肌肉流失,使其成为一种潜在的高质量体重控制候选药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 来凯医药-B盘中大涨5.24%,肥胖症新药LAE102进入I期临床试验","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02105"],"gpt_icon":0},{"id":"2522853453","title":"來凱醫藥-B(02105.HK):LAE102針對肥胖症治療的I期多劑量遞增研究完成首例受試者訪視","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853453","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853453?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 08:13","pubTimestamp":1742948020,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨来凯医药-B发布公告,集团在中国开展的LAE102针对肥胖症治疗的I期多剂量递增研究已启动受试者招募。截至本公告日期,首例受试者完成了首次访视。MAD研究是一项随机、双盲、安慰剂对照研究,旨在评估皮下给药的LAE102在60名超重╱肥胖受试者中的安全性、耐受性、药代动力学和药效动力学。LAE102与GLP-1受体激动剂联用可进一步减少脂肪并显著降低GLP-1受体激动剂导致的肌肉流失,使LAE102成为一种高质量体重控制候选药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/26081349046612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2522035006","title":"來凱醫藥(2105.HK)發佈2024年度業績:核心臨牀研究快於預期 加強全球化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2522035006","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522035006?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 08:44","pubTimestamp":1742863457,"startTime":"0","endTime":"0","summary":"来凯医药发布2024年度业绩,展示公司在高效推进临床及临床前候选药物开发,及全球化合作方面取得的重大进展。2024年第一季度,来凯向中国国家药品监督管理局药品审评中心及美国国家药品监督管理局提交了LAE102应用于肥胖适应症的新药临床研究申请,并于二季度获得批准。本集团保留LAE102的全球权益。目前研究招募工作正在进行中。2024年5月,公司获FDA批准此III期临床试验的方案。LAE120已于2025年2月获FDA临床试验申请批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032508441794bfa45f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032508441794bfa45f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2521377551","title":"來凱醫藥-B(02105)發佈年度業績,研發費用2.15億元 計劃在3月啓動在中國的I期MAD研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2521377551","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521377551?lang=zh_tw&edition=fundamental","pubTime":"2025-03-24 22:56","pubTimestamp":1742828166,"startTime":"0","endTime":"0","summary":"智通财经APP讯,来凯医药-B 发布至2024年12月31日止年度业绩,该集团取得研发费用人民币2.15亿元,同比减少6.67%;年内亏损2.54亿元,同比减少31.05%;每股亏损0.71元。LAE103是ActRIIB选择性抗体,LAE123是针对ActRIIA/IIB的双靶点抑制剂。本集团计划在2025年3月启动在中国的I期MAD研究。中国I期MAD研究是一项随机、双盲、安慰剂对照研究,旨在评估皮下给药的LAE102在60名超重╱肥胖受试者中的安全性、耐受性、药代动力学和药效动力学。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1266828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2521282470","title":"來凱醫藥-B03月21日遭主力拋售53萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2521282470","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521282470?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 16:16","pubTimestamp":1742544993,"startTime":"0","endTime":"0","summary":"03月21日, 来凯医药-B股价跌8.07%,报收13.22元,成交金额5948万元,换手率1.06%,振幅12.80%,量比2.11。来凯医药-B今日主力资金净流出53万元,上一交易日主力净流出50万元。该股近5个交易日下跌2.80%,主力资金累计净流入84万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入3634万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321170444a69eae76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321170444a69eae76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2520597138","title":"來凱醫藥-B03月19日主力淨流入258萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2520597138","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520597138?lang=zh_tw&edition=fundamental","pubTime":"2025-03-19 16:15","pubTimestamp":1742372126,"startTime":"0","endTime":"0","summary":"03月19日, 来凯医药-B股价涨2.07%,报收13.80元,成交金额1594万元,换手率0.28%,振幅8.43%,量比0.35。来凯医药-B今日主力资金净流入258万元,上一交易日主力净流出73万元。该股近5个交易日下跌0.14%,主力资金累计净流入267万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入4733万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250319165102a43974a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250319165102a43974a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2518085101","title":"來凱醫藥-B盤中異動 快速拉昇5.19%報13.380港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518085101","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518085101?lang=zh_tw&edition=fundamental","pubTime":"2025-03-12 09:36","pubTimestamp":1741743384,"startTime":"0","endTime":"0","summary":"2025年03月12日早盘09时36分,来凯医药-B股票出现异动,股价快速拉升5.19%。截至发稿,该股报13.380港元/股,成交量18.6万股,换手率0.05%,振幅9.43%。资金方面,该股资金流入128.237万港元,流出37.271万港元。来凯医药-B股票所在的生物技术行业中,整体涨幅为0.25%。其相关个股中,帝王国际投资、百奥赛图-B、歌礼制药-B涨幅较大,振幅较大的相关个股有来凯医药-B、和铂医药-B、金斯瑞生物科技,振幅分别为8.96%、8.28%、7.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250312093624a1d6aff4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250312093624a1d6aff4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2518730664","title":"來凱醫藥-B盤中異動 早盤股價大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518730664","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518730664?lang=zh_tw&edition=fundamental","pubTime":"2025-03-11 09:30","pubTimestamp":1741656605,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘09时30分,来凯医药-B股票出现波动,股价快速下挫5.04%。截至发稿,该股报12.060港元/股,成交量6500股,换手率0.00%,振幅4.25%。来凯医药-B股票所在的生物技术行业中,整体跌幅为0.01%。其相关个股中,荃信生物-B、基石药业-B、东曜药业-B涨幅较大,振幅较大的相关个股有欧康维视生物-B、来凯医药-B、科济药业-B,振幅分别为4.42%、4.25%、3.80%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503110930059640c905&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503110930059640c905&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2518254852","title":"港股通證券名單調整 被剔出個股股價普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2518254852","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518254852?lang=zh_tw&edition=fundamental","pubTime":"2025-03-10 10:12","pubTimestamp":1741572727,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上交所和深交所分别发布公告称,鉴于恒生综合大型股指数、中型股指数、小型股指数实施成份股定期调整,相应对纳入及调出港股通交易范围的证券名单进行调整,此次调整于3月10日生效。调整生效后,被剔出港股通名单的个股股价普遍呈现下跌态势。其中,京基金融国际(01468)表现最为疲软,当前股价下跌32%,报0.255港元。此外,宜明昂科-B(01541)股价下跌11.58%;来凯医药-B(02105)下跌16.69%;科济药业-B(02171)下跌14.32%;科笛(02487)下跌12.99%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954670","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01468","HSTECH","BK1585","02487","BK1574","01541","BK1161","BK1587","02105","BK1138","161027","BK4614","02171","YANG","07226","HSCEI","BK1181"],"gpt_icon":0},{"id":"2518258529","title":"深交所發佈關於深港通下的港股通標的證券名單調整的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2518258529","media":"深交所网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518258529?lang=zh_tw&edition=fundamental","pubTime":"2025-03-10 08:58","pubTimestamp":1741568314,"startTime":"0","endTime":"0","summary":"因恒生综合大型股指数、中型股指数、小型股指数实施成份股定期调整,根据《深圳证券交易所深港通业务实施办法》的有关规定,港股通标的证券名单发生调整并自2025年03月10日起生效,相关调整信息如下:","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00041","02510","BK1240","03309","00308","01468","02586","02678","01119","03669","06639","09959","02582","HSCEI","02105","02150","00659","02487","02562","HSTECH","02461","02432","02407","02431","02522","06698","09869","02570","01799","BK1582","00999","02506","01541","01600","02799","02410","02423","02171","02232","01268","00095","02121","00410","09985","00697","02507","BK1555","02411","06623","01318","02577","02587","06660","01942","03939","09966","03650","02460","00743"],"gpt_icon":0},{"id":"2517136782","title":"來凱醫藥-B03月06日獲主力加倉2196萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517136782","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517136782?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 16:17","pubTimestamp":1741249042,"startTime":"0","endTime":"0","summary":"03月06日, 来凯医药-B股价涨12.37%,报收14.90元,成交金额1.93亿元,换手率3.23%,振幅15.69%,量比1.45。来凯医药-B今日主力资金净流入2196万元,连续3日净流入,上一交易日主力净流入211万元。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为50.00%,平均涨幅为8.26%。该股近5个交易日上涨15.53%,主力资金累计净流入2233万元;近20日主力资金累计净流入5531万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170309a2622cc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170309a2622cc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2517055799","title":"港股創新藥ETF漲超2.5%,來凱醫藥-B漲超11%,機構:具有高科技屬性的醫藥醫療公司將更受市場青睞","url":"https://stock-news.laohu8.com/highlight/detail?id=2517055799","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517055799?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:35","pubTimestamp":1741228542,"startTime":"0","endTime":"0","summary":"相关ETF方面,港股创新药ETF截至发稿涨2.52%,成交额超1亿元,换手率超20%,盘中交投活跃。港股创新药ETF紧密跟踪港股通创新药指数,该指数反映港股通生物科技产业上市公司的运行特征。财通证券表示,看多创新药政策新周期带来的产业链共振上升,看多AI对医药产业带来的中长期影响,具有高科技属性的医药医疗公司将更受市场青睐。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306104204a261a137&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306104204a261a137&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","02105","BK1161"],"gpt_icon":0},{"id":"2517903843","title":"來凱醫藥-B(02105)股價顯著上升14.178%,現價港幣$15.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903843","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517903843?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:20","pubTimestamp":1741227600,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药-B(02105) 股价在上午10:20比前收市价显著上升14.178%,现股价为港币$15.14。至目前为止,今日最高价为$15.14,而最低价为$13.28。总成交量为489.75万股,总成交金额为港币$6.959千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2503063955/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2517908528","title":"來凱醫藥-B盤中異動 大幅上漲5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908528","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517908528?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:55","pubTimestamp":1741226105,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时55分,来凯医药-B股票出现波动,股价急速拉升5.13%。截至发稿,该股报13.940港元/股,成交量150.9万股,换手率0.37%,振幅4.98%。来凯医药-B股票所在的生物技术行业中,整体涨幅为1.71%。其相关个股中,复宏汉霖、迈博药业-B、昭衍新药涨幅较大,振幅较大的相关个股有创胜集团-B、贝康医疗-B、复宏汉霖,振幅分别为11.18%、9.38%、8.57%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306095505abea77de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306095505abea77de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2516762512","title":"來凱醫藥-B03月04日主力淨流入185萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2516762512","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516762512?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:38","pubTimestamp":1741081121,"startTime":"0","endTime":"0","summary":"03月04日, 来凯医药-B股价涨2.97%,报收13.16元,成交金额8672万元,换手率1.62%,振幅12.05%,量比0.58。来凯医药-B今日主力资金净流入185万元,上一交易日主力净流出256万元。该股近5个交易日上涨6.46%,主力资金累计净流入827万元;近20日主力资金累计净流入3219万元,其中净流入天数为12日。该股主力净额占比0.03%,港股市场排名133/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174426a25ea528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174426a25ea528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2516558697","title":"港股異動 | 來凱醫藥-B(02105)再漲近5% 公司自研新藥LAE120獲美國FDA臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516558697","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516558697?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:23","pubTimestamp":1741054980,"startTime":"0","endTime":"0","summary":"来凯医药-B再涨近5%,截至发稿,涨4.85%,报13.4港元,成交额3360.26万港元。消息面上,来凯医药昨日宣布,美国食品药品监督管理局已批准其自主研发的LAE120,一种强效、高选择性USP1抑制剂的新药临床试验申请,用于治疗晚期实体瘤患者。公司表示正积极开展外部合作以加快LAE120临床开发进展。来凯医药首席执行官吕向阳博士表示,来凯又一款早期研发项目获批IND,体现了来凯在新药研发领域的实力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-04/doc-inenncvp9980225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03347","BK1583","BK1141","BK1161","02105","BK1576"],"gpt_icon":0},{"id":"2516691044","title":"來凱醫藥-B盤中異動 股價大跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516691044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516691044?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 09:31","pubTimestamp":1741051906,"startTime":"0","endTime":"0","summary":"2025年03月04日早盘09时31分,来凯医药-B股票出现异动,股价大幅跳水5.16%。截至发稿,该股报12.120港元/股,成交量22.5万股,换手率0.06%,振幅9.55%。资金方面,该股资金流入39.388万港元,流出163.835万港元。来凯医药-B股票所在的生物技术行业中,整体跌幅为2.38%。其相关个股中,同源康医药-B、科笛-B、康宁杰瑞制药-B涨幅较大,振幅较大的相关个股有乐普生物-B、来凯医药-B、科笛-B,振幅分别为9.63%、9.55%、8.85%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304093146989ab776&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304093146989ab776&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2516650004","title":"來凱醫藥-B03月03日遭主力拋售256萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516650004","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516650004?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 16:15","pubTimestamp":1740989754,"startTime":"0","endTime":"0","summary":"03月03日, 来凯医药-B股价涨2.08%,报收12.78元,成交金额1.81亿元,换手率3.31%,振幅12.94%,量比1.40。来凯医药-B今日主力资金净流出256万元,连续3日净流出,上一交易日主力净流出105万元。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为83.33%,平均跌幅为4.45%。该股近5个交易日上涨10.73%,主力资金累计净流入1257万元;近20日主力资金累计净流入3034万元,其中净流入天数为11日。该股主力净额占比0.05%,港股市场排名2550/2649。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303165308abe5c278&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303165308abe5c278&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02105\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"02105","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-16","symbol":"02105","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723771800000,"name":null,"time":"盤後","dateTimestamp":1723737600000,"actualEps":null},{"date":"2024-03-26","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711416600000,"name":null,"time":"","dateTimestamp":1711382400000,"actualEps":null},{"date":"2023-08-24","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692840600000,"name":null,"time":"","dateTimestamp":1692806400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02105\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02105\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02105\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02105","date":"2025-04-17","current":-15.831036,"percent":0.067265,"low":-20.235293,"twenty":-11.83884,"median":-7.042573,"eighty":-4.481028,"high":-1.640852,"avg":-8.190906,"sd":4.277952,"marketCap":4281657466},"quantilePoints":[{"date":"2023-06-30","current":-7.785551,"twenty":-6.73679,"median":-5.163648,"eighty":-3.590506,"marketCap":6577091901},{"date":"2023-07-07","current":-6.912426,"twenty":-7.480081,"median":-7.023469,"eighty":-6.753459,"marketCap":5828099229},{"date":"2023-07-14","current":-6.415246,"twenty":-7.354402,"median":-6.80281,"eighty":-6.620389,"marketCap":5484810921},{"date":"2023-07-21","current":-6.50021,"twenty":-7.00126,"median":-6.637911,"eighty":-6.415921,"marketCap":5531622963},{"date":"2023-07-28","current":-6.387862,"twenty":-6.910347,"median":-6.626959,"eighty":-6.393338,"marketCap":5430196872},{"date":"2023-08-04","current":-6.872048,"twenty":-6.916775,"median":-6.645885,"eighty":-6.415921,"marketCap":5851505250},{"date":"2023-08-11","current":-8.062915,"twenty":-7.354402,"median":-6.732662,"eighty":-6.423028,"marketCap":6826756125},{"date":"2023-08-18","current":-6.496848,"twenty":-7.428921,"median":-6.729682,"eighty":-6.45189,"marketCap":5461404900},{"date":"2023-08-25","current":-8.440637,"twenty":-7.525288,"median":-6.804775,"eighty":-6.49752,"marketCap":6327427677},{"date":"2023-09-01","current":-9.089804,"twenty":-8.007442,"median":-6.902032,"eighty":-6.501491,"marketCap":6842360139},{"date":"2023-09-08","current":-6.586545,"twenty":-8.136633,"median":-6.907229,"eighty":-6.507456,"marketCap":4899660396},{"date":"2023-09-15","current":-5.932237,"twenty":-8.007442,"median":-6.869978,"eighty":-6.423028,"marketCap":4447143990},{"date":"2023-09-22","current":-6.606383,"twenty":-7.784235,"median":-6.883282,"eighty":-6.45189,"marketCap":4930868424},{"date":"2023-09-29","current":-7.14814,"twenty":-7.744431,"median":-6.894516,"eighty":-6.45189,"marketCap":5344374795},{"date":"2023-10-06","current":-7.631816,"twenty":-7.631816,"median":-6.912426,"eighty":-6.496848,"marketCap":5703267117},{"date":"2023-10-13","current":-8.856112,"twenty":-8.155063,"median":-6.923868,"eighty":-6.50021,"marketCap":6608299929},{"date":"2023-10-20","current":-8.199572,"twenty":-8.313082,"median":-7.000277,"eighty":-6.506614,"marketCap":6108971481},{"date":"2023-10-27","current":-9.816471,"twenty":-8.453817,"median":-7.029823,"eighty":-6.509983,"marketCap":7310480559},{"date":"2023-11-03","current":-11.65035,"twenty":-8.539495,"median":-7.190868,"eighty":-6.562195,"marketCap":8699237805},{"date":"2023-11-10","current":-10.973476,"twenty":-8.805599,"median":-7.285091,"eighty":-6.584244,"marketCap":8192107350},{"date":"2023-11-17","current":-11.729885,"twenty":-9.08956,"median":-7.4166,"eighty":-6.600627,"marketCap":8835772927},{"date":"2023-11-24","current":-11.685472,"twenty":-9.394133,"median":-7.490817,"eighty":-6.605936,"marketCap":8874782962},{"date":"2023-12-01","current":-9.84176,"twenty":-10.15546,"median":-7.577915,"eighty":-6.610422,"marketCap":7505530734},{"date":"2023-12-08","current":-7.796477,"twenty":-9.900606,"median":-7.778973,"eighty":-6.615093,"marketCap":5921723313},{"date":"2023-12-15","current":-9.518573,"twenty":-9.821529,"median":-7.782262,"eighty":-6.63353,"marketCap":7271470524},{"date":"2023-12-22","current":-9.095699,"twenty":-9.838318,"median":-7.864399,"eighty":-6.64429,"marketCap":6943786230},{"date":"2023-12-29","current":-10.114857,"twenty":-10.007865,"median":-8.108989,"eighty":-6.673018,"marketCap":7762996965},{"date":"2024-01-05","current":-7.064143,"twenty":-9.846254,"median":-7.963657,"eighty":-6.71691,"marketCap":5383384830},{"date":"2024-01-12","current":-6.507833,"twenty":-9.8409,"median":-7.785551,"eighty":-6.71691,"marketCap":4962076452},{"date":"2024-01-19","current":-6.147909,"twenty":-9.833261,"median":-7.674627,"eighty":-6.639506,"marketCap":4681204200},{"date":"2024-01-26","current":-4.037471,"twenty":-9.789285,"median":-7.606263,"eighty":-6.604594,"marketCap":3062287747},{"date":"2024-02-02","current":-1.910591,"twenty":-9.668744,"median":-7.523229,"eighty":-6.508431,"marketCap":1447272298},{"date":"2024-02-09","current":-1.972972,"twenty":-9.600955,"median":-7.449769,"eighty":-6.45189,"marketCap":1501886347},{"date":"2024-02-16","current":-2.11088,"twenty":-9.539168,"median":-7.4166,"eighty":-6.417948,"marketCap":1607213442},{"date":"2024-02-23","current":-1.782124,"twenty":-9.334553,"median":-7.285091,"eighty":-6.285716,"marketCap":1349747211},{"date":"2024-03-01","current":-3.73704,"twenty":-9.184661,"median":-7.220535,"eighty":-6.16588,"marketCap":2832128541},{"date":"2024-03-08","current":-3.812556,"twenty":-9.158571,"median":-7.14814,"eighty":-5.783471,"marketCap":2890643593},{"date":"2024-03-15","current":-3.774736,"twenty":-9.108268,"median":-7.054895,"eighty":-5.122231,"marketCap":2859435565},{"date":"2024-03-22","current":-3.314294,"twenty":-9.090983,"median":-7.029823,"eighty":-4.16949,"marketCap":2508345250},{"date":"2024-03-28","current":-5.557677,"twenty":-9.089621,"median":-7.000277,"eighty":-4.108477,"marketCap":2219670991},{"date":"2024-04-05","current":-4.994454,"twenty":-9.061533,"median":-6.958518,"eighty":-4.159233,"marketCap":1993412788},{"date":"2024-04-12","current":-4.698569,"twenty":-8.939101,"median":-6.914215,"eighty":-4.187247,"marketCap":1876382683},{"date":"2024-04-19","current":-5.074098,"twenty":-8.895252,"median":-6.907229,"eighty":-4.270544,"marketCap":2024620816},{"date":"2024-04-26","current":-6.049449,"twenty":-8.886537,"median":-6.872048,"eighty":-4.439166,"marketCap":2410820163},{"date":"2024-05-03","current":-6.122202,"twenty":-8.8768,"median":-6.815159,"eighty":-4.698569,"marketCap":2438127187},{"date":"2024-05-10","current":-6.43996,"twenty":-8.86224,"median":-6.755587,"eighty":-4.994454,"marketCap":2570761306},{"date":"2024-05-17","current":-7.203002,"twenty":-8.857338,"median":-6.782134,"eighty":-5.0499,"marketCap":2871138576},{"date":"2024-05-24","current":-4.794357,"twenty":-8.851703,"median":-6.739573,"eighty":-4.885401,"marketCap":2754108471},{"date":"2024-05-31","current":-4.572395,"twenty":-8.804497,"median":-6.721699,"eighty":-4.757241,"marketCap":2629276359},{"date":"2024-06-07","current":-4.421848,"twenty":-8.685949,"median":-6.645885,"eighty":-4.615745,"marketCap":2539553278},{"date":"2024-06-14","current":-3.882014,"twenty":-8.64394,"median":-6.616008,"eighty":-4.537135,"marketCap":2227472998},{"date":"2024-06-21","current":-3.862906,"twenty":-8.598267,"median":-6.605265,"eighty":-4.402835,"marketCap":2211868984},{"date":"2024-06-28","current":-3.550986,"twenty":-8.56584,"median":-6.575038,"eighty":-4.108477,"marketCap":2032422823},{"date":"2024-07-05","current":-3.292704,"twenty":-8.553381,"median":-6.507833,"eighty":-3.906941,"marketCap":1884184690},{"date":"2024-07-12","current":-3.669077,"twenty":-8.541472,"median":-6.498529,"eighty":-3.863311,"marketCap":2102640886},{"date":"2024-07-19","current":-2.927038,"twenty":-8.530589,"median":-6.44065,"eighty":-3.81922,"marketCap":1677431505},{"date":"2024-07-26","current":-2.773786,"twenty":-8.516747,"median":-6.41868,"eighty":-3.760814,"marketCap":1595510431},{"date":"2024-08-02","current":-3.12148,"twenty":-8.510893,"median":-6.387862,"eighty":-3.652511,"marketCap":1794461610},{"date":"2024-08-09","current":-2.9997,"twenty":-8.480176,"median":-6.325017,"eighty":-3.53511,"marketCap":1735946557},{"date":"2024-08-16","current":-3.214159,"twenty":-8.413826,"median":-6.28512,"eighty":-3.427,"marketCap":1860778669},{"date":"2024-08-23","current":-6.604067,"twenty":-8.372166,"median":-6.272718,"eighty":-3.478589,"marketCap":2129947911},{"date":"2024-08-30","current":-6.163541,"twenty":-8.347233,"median":-6.28512,"eighty":-3.497821,"marketCap":2001214795},{"date":"2024-09-06","current":-5.314921,"twenty":-8.300967,"median":-6.252611,"eighty":-3.516857,"marketCap":1726510663},{"date":"2024-09-13","current":-5.032211,"twenty":-8.277822,"median":-6.194778,"eighty":-3.53511,"marketCap":1630395636},{"date":"2024-09-20","current":-5.111432,"twenty":-8.256206,"median":-6.170373,"eighty":-3.56099,"marketCap":1665993794},{"date":"2024-09-27","current":-6.057967,"twenty":-8.195708,"median":-6.135055,"eighty":-3.605108,"marketCap":1986377216},{"date":"2024-10-04","current":-7.03444,"twenty":-8.180254,"median":-6.166957,"eighty":-3.621517,"marketCap":2296081191},{"date":"2024-10-10","current":-6.311883,"twenty":-8.160101,"median":-6.193894,"eighty":-3.641637,"marketCap":2046894085},{"date":"2024-10-18","current":-9.026405,"twenty":-8.160101,"median":-6.241014,"eighty":-3.658355,"marketCap":2911929324},{"date":"2024-10-25","current":-10.329157,"twenty":-8.288852,"median":-6.25781,"eighty":-3.667517,"marketCap":3331987588},{"date":"2024-11-01","current":-10.068556,"twenty":-8.453817,"median":-6.28512,"eighty":-3.723447,"marketCap":3250111825},{"date":"2024-11-08","current":-11.890039,"twenty":-8.539495,"median":-6.303819,"eighty":-3.748634,"marketCap":3809002906},{"date":"2024-11-15","current":-12.473246,"twenty":-8.638855,"median":-6.337113,"eighty":-3.770095,"marketCap":3965634801},{"date":"2024-11-22","current":-15.548537,"twenty":-8.857338,"median":-6.401271,"eighty":-3.792036,"marketCap":4941024330},{"date":"2024-11-29","current":-16.918042,"twenty":-8.907392,"median":-6.418623,"eighty":-3.798946,"marketCap":5372620800},{"date":"2024-12-06","current":-17.028741,"twenty":-9.08956,"median":-6.440305,"eighty":-3.809963,"marketCap":5395037855},{"date":"2024-12-13","current":-14.037501,"twenty":-9.184661,"median":-6.496848,"eighty":-3.825885,"marketCap":4438576850},{"date":"2024-12-20","current":-10.693671,"twenty":-9.519989,"median":-6.507224,"eighty":-3.843767,"marketCap":3366294395},{"date":"2024-12-27","current":-10.761363,"twenty":-9.613258,"median":-6.510825,"eighty":-3.853605,"marketCap":3384975274},{"date":"2025-01-03","current":-12.815569,"twenty":-9.789285,"median":-6.563121,"eighty":-3.862906,"marketCap":4035069864},{"date":"2025-01-10","current":-14.889249,"twenty":-9.925093,"median":-6.595306,"eighty":-3.863109,"marketCap":4670219750},{"date":"2025-01-17","current":-11.842286,"twenty":-10.213871,"median":-6.606383,"eighty":-3.864484,"marketCap":3717494921},{"date":"2025-01-24","current":-10.786847,"twenty":-10.358151,"median":-6.624251,"eighty":-3.867614,"marketCap":3407392329},{"date":"2025-01-28","current":-10.88357,"twenty":-10.395234,"median":-6.635203,"eighty":-3.869357,"marketCap":3455962615},{"date":"2025-02-07","current":-10.247352,"twenty":-10.395234,"median":-6.668158,"eighty":-3.877648,"marketCap":3235528242},{"date":"2025-02-14","current":-10.714001,"twenty":-10.679993,"median":-6.721699,"eighty":-3.919404,"marketCap":3381239099},{"date":"2025-02-21","current":-14.934496,"twenty":-10.737429,"median":-6.739573,"eighty":-3.995096,"marketCap":4729998562},{"date":"2025-02-28","current":-14.81818,"twenty":-10.833722,"median":-6.801774,"eighty":-4.034059,"marketCap":4677692101},{"date":"2025-03-07","current":-17.375919,"twenty":-11.045086,"median":-6.869978,"eighty":-4.108477,"marketCap":5507123129},{"date":"2025-03-14","current":-16.002657,"twenty":-11.141514,"median":-6.898274,"eighty":-4.166071,"marketCap":5073726736},{"date":"2025-03-21","current":-15.584553,"twenty":-11.292034,"median":-6.914215,"eighty":-4.215924,"marketCap":4939224407},{"date":"2025-03-28","current":-19.960729,"twenty":-11.418322,"median":-6.958518,"eighty":-4.322429,"marketCap":5432399613},{"date":"2025-04-03","current":-17.71685,"twenty":-11.522026,"median":-7.011873,"eighty":-4.393328,"marketCap":4812194430},{"date":"2025-04-11","current":-14.733536,"twenty":-11.702518,"median":-7.03444,"eighty":-4.445369,"marketCap":3975291051},{"date":"2025-04-17","current":-15.831036,"twenty":-11.83884,"median":-7.042573,"eighty":-4.481028,"marketCap":4281657466}],"updateTime":1745050088202}}}